Cholinergic neuronal loss in DS may also be driven by neuroinflammation, as treatment of Ts65Dn mice with the anti-inflammatory compound minocycline or anti-IL17 prevented cholinergic degeneration in the MSN and stopped the microglial activation or raised cytokine abundance, respectively, seen in untreated mice (Hunter et al., 2004a; Rueda et al., 2018). This evidence concerns the gene IL17A and Dravet syndrome.